查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953755

食物過敏治療市場－全球產業規模、佔有率、趨勢、機會及預測（依過敏原類型、藥物類型、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年）

Food Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Allergen Type, By Drug Type, By Route of Administration, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球食物過敏治療市場預計將從 2025 年的 71.5 億美元成長到 2031 年的 115.3 億美元，複合年成長率達到 8.29%。

該領域涉及藥物干預和免疫療法的研發和商業化，旨在降低免疫系統的敏感性，並控制由特定食物蛋白引發的急性過敏反應。推動這一領域成長的關鍵因素是全球範圍內對花生、牛奶和雞蛋等過敏原的致敏率迅速​​上升，這使得人們對有效的臨床管理策略（而不僅僅是避免接觸過敏原）的需求顯著增加。此外，近期生物製藥製劑的核准上市也大大促進了該領域的發展，為醫療保健提供者提供了一種降低過敏反應嚴重程度的新機制。

市場概覽
預測期 2027-2031
市場規模：2025年 71.5億美元
市場規模：2031年 115.3億美元
複合年成長率：2026-2031年 8.29%
成長最快的細分市場 腎上腺素
最大的市場 北美洲

然而，這個市場面臨著許多障礙，包括新型治療方法的高成本和複雜的報銷機制，這些因素常常限制了患者的廣泛獲取。這些經濟障礙阻礙了不同人群公平地獲得改變人生的治療方法。根據美國食品過敏研究與教育組織（FARE）2024年的報告顯示，美國約有3,300萬人患有危及生命的食物過敏，這凸顯了巨大的潛在市場，但其發展仍部分受限於價格承受能力方面的挑戰。

市場促進因素

創新免疫療法和生物製藥的快速普及正在從根本上改變全球食物過敏治療市場，使臨床治療不再局限於權宜之計。這項轉變得益於近期監管方面的進展，為醫療專業人員提供了第一個能夠同時減輕多種過敏原反應嚴重程度的藥物選擇。例如，在2024年2月發布的新聞稿《FDA核准Zolia成為首個也是目前唯一一個用於治療兒童和成人一種或多種食物過敏的藥物》中，基因泰克公司報告稱，臨床試驗表明，接受Zolia治療16至20週的患者中，68%能夠耐受至少600毫克花生蛋白而無中度至重度症狀，而安慰劑組僅有標準。如此顯著的療效數據促使生物製藥迅速整合到標準治療通訊協定中，直接擴大了治療性介入的潛在市場。

同時，兒童和成人嚴重食物過敏在全球範圍內的日益普遍，也使得這些緩解疾病治療方法的研發變得尤為迫切。面臨生命危險的患者群體的存在顯著影響著市場趨勢，導致預防過敏性休克的治療方法存在著巨大的未滿足需求。根據美國疾病管制與預防中心 (CDC) 2024 年的數據，至少 40% 的食物過敏兒童因過敏反應而在急診室接受治療，凸顯了疾病的嚴重性。如此沉重的疾病負擔正在推動大量的商業活動和研發投入。正如 DBV Technologies 在 2024 年 11 月發布的「2024 年第三季財報」中所述，該公司年初至今的營運支出預計將達到 9,640 萬美元，其中大部分將用於支持關鍵性臨床試驗的推進。

市場挑戰

全球食物過敏治療市場的商業性擴張受到新型治療方法高成本和複雜的健保報銷環境的顯著阻礙。儘管藥物研發的進步帶來了新的脫敏機制，但這些生物製藥生產商收取高昂的標價。因此，醫療保險公司通常將這些治療方法歸類為非必需療法，或將其列入高額自付費用等級，從而造成經濟障礙，限制了患者的接受度。臨床可近性和經濟可負擔性之間的這種差距限制了潛在市場規模，因為只有一小部分確診患者能夠負擔得起持續的治療費用，從而抑制了生產商的收入成長。

這種經濟摩擦因受這些疾病影響的家庭本已承受的經濟負擔而進一步加劇。根據美國氣喘和過敏基金會 (AAFA) 2025 年的預測，經通​​貨膨脹調整後，每年照顧食物過敏兒童的經濟成本約為 340 億美元。這一驚人的數字表明，這些家庭已經承受著沉重的經濟負擔，而昂貴的藥物治療費用對許多家庭來說更是難以承受。因此，市場難以將高昂的臨床需求轉化為持續的治療普及。

市場趨勢

隨著無針替代方案（尤其是鼻用腎上腺素噴霧劑）的商業化，急救領域正在經歷重大變革，這些方案正在取代傳統的自動注射器。這一趨勢直接解決了諸如對針頭的恐懼和笨重設備的使用障礙等重大問題，這些問題曾導致在過敏性休克發作期間救命藥物的給藥延誤。製造商目前正利用積極的定價策略和合作模式，以確保這些新型給藥系統能夠快速滲透市場並惠及廣大患者。例如，根據 GoodRx 於 2024 年 9 月發布的題為「neffy 宣佈零售藥局最低現金折扣價」的新聞稿，一項策略合作將使超過 7 萬家藥局能夠以 199 美元的價格購買兩支裝的 neffy 一次性裝置，從而顯著降低這項新技術帶來的經濟門檻。

同時，經皮免疫療法（EPIT）平台的研發正蓬勃發展。該平台透過皮膚給藥微量抗原，誘導免疫耐受，且全身副作用比口服途徑更少。這種非侵入性療法正迅速推進至後期臨床開發階段，旨在為可能無法耐受口服免疫療法相關胃腸道副作用的兒童患者提供更安全的脫敏方案。 DBV Technologies 在 2024 年 10 月的新聞稿「DBV 宣布 Viaskin 花生貼片法規核准取得積極進展」中，反映了該臨床開發的規模。新聞稿中指出，該公司已完成對改良花生貼片在兒童中療效評估的 III 期 VITESSE 試驗的受試者招募，總合招募了 654 名受試者。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球食物過敏治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依過敏原分類（乳製品、家禽、堅果、花生、貝類、小麥、大豆、其他）
    • 依藥物類型（抗組織胺藥物、腎上腺素、免疫療法）
    • 依給藥途徑（口服、腸外、其他）
    • 依最終用戶（醫院藥局、零售藥局、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美食物過敏治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲食物過敏治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區食物過敏治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲食物過敏治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲食物過敏治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球食物過敏治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Aimmune Therapeutics
  • DBV Technologies
  • Regeneron
  • Sanofi
  • Nestle Health Science
  • Novartis
  • Immune Design
  • TanGenix
  • Allergen Labs
  • 與FARE相關的創新者

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 26678

The Global Food Allergy Treatment Market is projected to expand from USD 7.15 Billion in 2025 to USD 11.53 Billion by 2031, achieving a CAGR of 8.29%. This sector encompasses the development and commercialization of pharmaceutical interventions and immunotherapies aimed at desensitizing the immune system or managing acute anaphylactic reactions triggered by specific dietary proteins. The primary force driving this growth is the rapidly rising global prevalence of sensitization to allergens like peanuts, milk, and eggs, which creates a critical demand for effective clinical management strategies beyond simple avoidance. Furthermore, the recent regulatory approval and launch of biologic agents that facilitate desensitization are significantly boosting the sector by offering healthcare providers new mechanisms to reduce the severity of allergic reactions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.15 Billion
Market Size 2031USD 11.53 Billion
CAGR 2026-20318.29%
Fastest Growing SegmentEpinephrine
Largest MarketNorth America

However, the market confronts a major obstacle regarding the high cost of new therapies and a complicated reimbursement environment that frequently limits broad patient access. These financial hurdles often obstruct the equitable availability of life-altering treatments across various demographic groups. As reported by Food Allergy Research & Education in 2024, approximately 33 million individuals in the United States were living with life-threatening food allergies, underscoring a massive addressable market that remains partially restricted by affordability challenges.

Market Driver

The rapid adoption of innovative immunotherapies and biologics is fundamentally transforming the Global Food Allergy Treatment Market, shifting clinical care beyond mere avoidance tactics. This evolution is underpinned by recent regulatory achievements that provide medical professionals with the first pharmaceutical options capable of reducing reaction severity across multiple allergens simultaneously. For instance, Genentech reported in a February 2024 press release titled 'FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies' that clinical trials showed 68% of patients treated with Xolair for 16 to 20 weeks could tolerate at least 600 mg of peanut protein without moderate to severe symptoms, compared to only 5% of the placebo group. Such strong efficacy data encourages the swift integration of biologic agents into standard treatment protocols, directly broadening the addressable market for therapeutic interventions.

Simultaneously, the increasing global prevalence of severe food allergies in both children and adults is heightening the urgency for these disease-modifying solutions. The market's trajectory is heavily influenced by a patient population facing life-threatening risks, resulting in a critical unmet need for treatments that prevent anaphylaxis. Data from the Centers for Disease Control and Prevention in 2024 indicates that at least 40% of children with food allergies have been treated in the emergency department for reactions, highlighting the condition's severity. This significant disease burden drives substantial commercial activity and development spending; as noted by DBV Technologies in their 'Third Quarter 2024 Financial Results' from November 2024, operating expenses reached $96.4 million for the first nine months of the year, primarily to support the advancement of pivotal clinical trials.

Market Challenge

The commercial expansion of the Global Food Allergy Treatment Market is significantly hindered by the high cost of novel therapies and a complex reimbursement landscape. Although pharmaceutical advancements provide new desensitization mechanisms, the extensive research and development investments required for these biologics compel manufacturers to set premium list prices. Consequently, health insurers often categorize these treatments as non-essential or place them in tiers with high out-of-pocket costs, creating a financial barrier that restricts patient adoption. This gap between clinical availability and economic accessibility limits the serviceable addressable market, as only a fraction of the diagnosed population can afford continuous therapy, thereby stalling revenue growth for manufacturers.

This financial friction is further exacerbated by the existing economic burden placed on families managing these conditions. The Asthma and Allergy Foundation of America estimated in 2025 that the inflation-adjusted annual economic cost of caring for children with food allergies was approximately $34 billion. This substantial figure illustrates the heavy financial load already borne by households, making the additional expense of high-priced pharmaceutical interventions untenable for many. As a result, the market struggles to convert high clinical demand into sustained therapeutic adoption.

Market Trends

The emergency response segment is undergoing a significant transition from traditional auto-injectors to needle-free alternatives, specifically with the commercialization of intranasal epinephrine sprays. This trend directly targets critical barriers such as needle phobia and device bulkiness, which have historically delayed the administration of life-saving medication during anaphylactic events. Manufacturers are currently utilizing aggressive pricing strategies and partnership models to ensure these novel delivery systems rapidly penetrate the market and become accessible to a broad patient base. For example, according to a September 2024 press release by GoodRx titled 'GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy,' a strategic partnership was established to allow consumers to access a pack of two single-use neffy devices for $199 at over 70,000 pharmacies, significantly lowering the financial hurdle for this new technology.

At the same time, the market is seeing a surge in the development of Epicutaneous Immunotherapy (EPIT) platforms, which deliver micro-doses of allergens through the skin to induce tolerance with fewer systemic side effects than oral routes. This non-invasive approach is rapidly moving through late-stage clinical pipelines, aiming to provide a safer desensitization option for pediatric patients who may not tolerate the gastrointestinal side effects associated with oral immunotherapy. Reflecting the substantial scale of this clinical development, DBV Technologies announced in an October 2024 press release titled 'DBV Announces Positive Regulatory Updates for the Viaskin Peanut Patch' that the company successfully enrolled a total of 654 subjects in the Phase 3 VITESSE efficacy trial to evaluate the modified peanut patch in children.

Key Market Players

  • Aimmune Therapeutics
  • DBV Technologies
  • Regeneron
  • Sanofi
  • Nestle Health Science
  • Novartis
  • Immune Design
  • TanGenix
  • Allergen Labs
  • FARE-associated Innovators

Report Scope

In this report, the Global Food Allergy Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Food Allergy Treatment Market, By Allergen Type

  • Dairy Products
  • Poultry Product
  • Tree Nuts
  • Peanuts
  • Shellfish
  • Wheat
  • Soys
  • Other

Food Allergy Treatment Market, By Drug Type

  • Antihistamines
  • Epinephrine
  • Immunotherapy

Food Allergy Treatment Market, By Route of Administration

  • Oral
  • Parenteral
  • Other

Food Allergy Treatment Market, By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Food Allergy Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Food Allergy Treatment Market.

Available Customizations:

Global Food Allergy Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Food Allergy Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Allergen Type (Dairy Products, Poultry Product, Tree Nuts, Peanuts, Shellfish, Wheat, Soys, Other)
    • 5.2.2. By Drug Type (Antihistamines, Epinephrine, Immunotherapy)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Other)
    • 5.2.4. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Food Allergy Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Allergen Type
    • 6.2.2. By Drug Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Food Allergy Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Allergen Type
        • 6.3.1.2.2. By Drug Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Food Allergy Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Allergen Type
        • 6.3.2.2.2. By Drug Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Food Allergy Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Allergen Type
        • 6.3.3.2.2. By Drug Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By End User

7. Europe Food Allergy Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Allergen Type
    • 7.2.2. By Drug Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Food Allergy Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Allergen Type
        • 7.3.1.2.2. By Drug Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
    • 7.3.2. France Food Allergy Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Allergen Type
        • 7.3.2.2.2. By Drug Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Food Allergy Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Allergen Type
        • 7.3.3.2.2. By Drug Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Food Allergy Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Allergen Type
        • 7.3.4.2.2. By Drug Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Food Allergy Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Allergen Type
        • 7.3.5.2.2. By Drug Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By End User

8. Asia Pacific Food Allergy Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Allergen Type
    • 8.2.2. By Drug Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Food Allergy Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Allergen Type
        • 8.3.1.2.2. By Drug Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
    • 8.3.2. India Food Allergy Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Allergen Type
        • 8.3.2.2.2. By Drug Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Food Allergy Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Allergen Type
        • 8.3.3.2.2. By Drug Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Food Allergy Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Allergen Type
        • 8.3.4.2.2. By Drug Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Food Allergy Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Allergen Type
        • 8.3.5.2.2. By Drug Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End User

9. Middle East & Africa Food Allergy Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Allergen Type
    • 9.2.2. By Drug Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Food Allergy Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Allergen Type
        • 9.3.1.2.2. By Drug Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Food Allergy Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Allergen Type
        • 9.3.2.2.2. By Drug Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Food Allergy Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Allergen Type
        • 9.3.3.2.2. By Drug Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User

10. South America Food Allergy Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Allergen Type
    • 10.2.2. By Drug Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Food Allergy Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Allergen Type
        • 10.3.1.2.2. By Drug Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Food Allergy Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Allergen Type
        • 10.3.2.2.2. By Drug Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Food Allergy Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Allergen Type
        • 10.3.3.2.2. By Drug Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Food Allergy Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Aimmune Therapeutics
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. DBV Technologies
  • 15.3. Regeneron
  • 15.4. Sanofi
  • 15.5. Nestle Health Science
  • 15.6. Novartis
  • 15.7. Immune Design
  • 15.8. TanGenix
  • 15.9. Allergen Labs
  • 15.10. FARE-associated Innovators

16. Strategic Recommendations

17. About Us & Disclaimer